Literature DB >> 21734780

Comorbidity in inflammatory bowel disease.

Antonio López San Román1, Fernando Muñoz.   

Abstract

Patients with inflammatory bowel disease (IBD) can be affected by other unrelated diseases. These are called comorbid conditions, and can include any secondary health problem that affects a person suffering from a primary or main disease, and which is neither linked physiopathologically to the primary condition, nor is it due to the treatments used for the primary condition or to its long-term anatomical or physiological consequences. Different comorbid conditions, as well as their influence on IBD, are discussed.

Entities:  

Keywords:  Comorbid conditions; Comorbidity; Crohn’s disease; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Year:  2011        PMID: 21734780      PMCID: PMC3122260          DOI: 10.3748/wjg.v17.i22.2723

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  141 in total

1.  Portal vein thrombosis in ulcerative colitis complicated by bleeding from gastric varices.

Authors:  Julia Palkovits; Michael Häfner; Thomas Rand; Harald Vogelsang; Mathilde Kutilek; Alfred Gangl; Gottfried Novacek
Journal:  Inflamm Bowel Dis       Date:  2007-03       Impact factor: 5.325

2.  Central retinal vein thrombosis in a patient with ulcerative colitis.

Authors:  Alan L Buchman; Anna Marie Babbo; Richard G Gieser
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

Review 3.  The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence.

Authors:  Robert G Maunder; Susan Levenstein
Journal:  Curr Mol Med       Date:  2008-06       Impact factor: 2.222

4.  Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France.

Authors:  Jean-Baptiste Chevaux; Abdelbasset Nani; Abderrahim Oussalah; Véronique Venard; Mouni Bensenane; Arthur Belle; Jean-Louis Gueant; Marc-André Bigard; Jean-Pierre Bronowicki; Laurent Peyrin-Biroulet
Journal:  Inflamm Bowel Dis       Date:  2010-06       Impact factor: 5.325

5.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

6.  Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project.

Authors:  Jordi Alonso; Montserrat Ferrer; Barbara Gandek; John E Ware; Neil K Aaronson; Paola Mosconi; Niels K Rasmussen; Monika Bullinger; Shunichi Fukuhara; Stein Kaasa; Alain Leplège
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

7.  Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County.

Authors:  Karen Vanessa Winther; Tine Jess; Ebbe Langholz; Pia Munkholm; Vibeke Binder
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

Review 8.  Updates in the treatment of gallstones.

Authors:  Sung Koo Lee; Myung-Hwan Kim
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-12       Impact factor: 3.869

9.  Liver and inflammatory bowel disease.

Authors:  S Nahon; J-F Cadranel; Olivier Chazouilleres; M Biour; V Jouannaud; P Marteau
Journal:  Gastroenterol Clin Biol       Date:  2009-04-24

10.  Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

Authors:  W Miehsler; W Reinisch; E Valic; W Osterode; W Tillinger; T Feichtenschlager; J Grisar; K Machold; S Scholz; H Vogelsang; G Novacek
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

View more
  27 in total

1.  Temporal comorbidity of mental disorder and ulcerative colitis.

Authors:  David Cawthorpe; Marta Davidson
Journal:  Perm J       Date:  2015

2.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

Review 3.  Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Authors:  Hubert Zatorski; Maciej Sałaga; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-29       Impact factor: 3.000

4.  The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases.

Authors:  G Conway; G Velonias; E Andrews; J J Garber; V Yajnik; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2017-01-20       Impact factor: 8.171

5.  Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.

Authors:  Benjamin Click; David G Binion; Alyce M Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-03       Impact factor: 11.382

Review 6.  Role of genetics in pediatric inflammatory bowel disease.

Authors:  David T Okou; Subra Kugathasan
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

Review 7.  The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects?

Authors:  Adrian L Lopresti
Journal:  Adv Nutr       Date:  2018-01-01       Impact factor: 8.701

Review 8.  Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.

Authors:  Ashwin N Ananthakrishnan; Tamara Donaldson; Karen Lasch; Vijay Yajnik
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

9.  Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Click; Claudia Ramos Rivers; Ioannis E Koutroubakis; Dmitriy Babichenko; Alyce M Anderson; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

10.  Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.

Authors:  Tessa E H Römkens; Rene Te Morsche; Wilbert Peters; David M Burger; Frank Hoentjen; Joost P H Drenth
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.